Results 211 to 220 of about 5,393,834 (251)

Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis

ESC Heart Failure, Volume 12, Issue 2, Page 1358-1373, April 2025.
Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen, Jiahao Shi, Yue Wu, Lizhu Miao, Zilin Wang, Yixuan Wang, Siwei Xu, Yu Lou   +7 more
wiley   +1 more source

CardiLect: A combined cross‐species lectin histochemistry protocol for the automated analysis of cardiac remodelling

ESC Heart Failure, Volume 12, Issue 2, Page 1398-1415, April 2025.
Abstract Background Cardiac remodelling, a crucial aspect of heart failure, is commonly investigated in preclinical models by quantifying cardiomyocyte cross‐sectional area (CSA) and microvascular density (MVD) via histological methods, such as immunohistochemistry.
Tamás G. Gergely, Tamás Kovács, Andrea Kovács, Viktória E. Tóth, Nabil V. Sayour, Gábor M. Mórotz, Csenger Kovácsházi, Gábor B. Brenner, Zsófia Onódi, Balázs Enyedi, Domokos Máthé, Przemyslaw Leszek, Zoltán Giricz, Péter Ferdinandy, Zoltán V. Varga   +14 more
wiley   +1 more source

Association of Systolic Blood Pressure Variability With Mortality, Coronary Heart Disease, Stroke, and Renal Disease. [PDF]

J Am Coll Cardiol, 2016
Gosmanova EO, Mikkelsen MK, Molnar MZ, Lu JL, Yessayan LT, Kalantar-Zadeh K, Kovesdy CP.   +6 more
europepmc   +1 more source

SPARCL1 and NT‐proBNP as biomarkers of right ventricular‐to‐pulmonary artery uncoupling in pulmonary hypertension

ESC Heart Failure, Volume 12, Issue 2, Page 1416-1426, April 2025.
Abstract Aims SPARCL1 was recently identified as a biomarker of right ventricular (RV) maladaptation in patients with pulmonary hypertension (PH), and N‐terminal pro‐brain natriuretic protein (NT‐proBNP) is an established biomarker of RV failure in PH. The present study investigated whether NT‐proBNP and SPARCL1 concentrations are associated with load ...
Oliver Dörr, Stanislav Keranov, Paulina van Wickern, Holger Nef, Christian Hamm, Pascal Bauer, Christian Troidl, Samuel Sossalla, Sandra Voss, Christoph Liebetrau, Manuel J. Richter, Henning Gall, Werner Seeger, Ardeschir Ghofrani, Athiththan Yogeswaran, Khodr Tello   +15 more
wiley   +1 more source

Association between within-visit systolic blood pressure variability and development of pre-diabetes and diabetes among overweight/obese individuals. [PDF]

J Hum Hypertens, 2017
Joshipura KJ, Muñoz-Torres FJ, Campos M, Rivera-Díaz AD, Zevallos JC.   +4 more
europepmc   +1 more source

Mortality risk stratification for Takotsubo syndrome: Evaluating CRP measurement alongside the InterTAK prognostic score

ESC Heart Failure, Volume 12, Issue 2, Page 1427-1436, April 2025.
Abstract Background and objectives Initially described as a benign acute cardiomyopathy, Takotsubo syndrome has been linked to elevated mortality rates. Emerging evidence suggests that unresolved myocardial inflammation may contribute to this adverse prognosis.
Loïc Faucher, Kensuke Matsushita, Shinnosuke Kikuchi, Taraneh Tatarcheh, Benjamin Marchandot, Amandine Granier, Said Amissi, Antonin Trimaille, Laurence Jesel, Patrick Ohlmann, Kiyoshi Hibi, Valérie Schini‐Kerth, Olivier Morel   +12 more
wiley   +1 more source

Systolic blood pressure variability in patients with early severe sepsis or septic shock: a prospective cohort study. [PDF]

BMC Anesthesiol, 2017
Tang Y, Sorenson J, Lanspa M, Grissom CK, Mathews VJ, Brown SM.   +5 more
europepmc   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

The association between Healthy Eating Index‐2020 and epilepsy: Insights based on NHANES from 2013 to 2018

Epileptic Disorders, EarlyView.
Abstract Background Epilepsy is a serious chronic brain disease. However, limited study is focused on the association between dietary pattern and epilepsy management. Hence, we aim to investigate the association between the Healthy Eating Index (HEI‐2020) and epilepsy odds.
Kun Yu, Yingxin Wang, Huaiqing Gao
wiley   +1 more source

Visit-to-visit systolic blood pressure variability and microvascular complications among patients with diabetes. [PDF]

J Diabetes Complications, 2017
Sohn MW, Epstein N, Huang ES, Huo Z, Emanuele N, Stukenborg G, Guihan M, Li J, Budiman-Mak E.   +8 more
europepmc   +1 more source